Introduction
The liver is the major organ involved in the elimination of potentially harmful endogenous and xenobiotic substances, including pharmaceutical drugs, and is itself predisposed to toxicity resulting from high exposure to drugs and their metabolites. Drug-induced liver injury (DILI) is a leading cause for acute liver failure, termination of compounds in drug development and drug withdrawal from the market (Lee, 2003; FDA, 2009) . The severity of DILI ranges from asymptomatic elevations of liver enzymes to acute liver failure and manifests with hepatocellular, cholestatic or mixed (hepatocellular/cholestatic) patterns.
Although drug-induced cholestasis (DIC) usually represents a less severe form of DILI, it is nevertheless reported to account for up to 26% of all hepatic adverse reactions (Bjornsson and Olsson, 2005; Hussaini and Farrington, 2007) . Cholestasis is characterized by reduced bile flow, potentially resulting in accumulation of cytotoxic bile salts within hepatocytes leading to liver damage (Stieger, 2010) . The bile salt export pump (BSEP), a member of the ATP-binding cassette superfamily encoded by the ABCB11 gene, is expressed at the canalicular membrane of hepatocytes and plays a fundamental role in bile homeostasis by secreting bile acids from the hepatocyte into bile ducts. Impairment of BSEP function due to inhibition by drugs or genetic defects was previously identified as a key factor in the development of DIC, hereditary cholestatic syndromes or intrahepatic cholestasis of pregnancy (Stieger et al., 2000; Fattinger et al., 2001; Funk et al., 2001; Pauli-Magnus et al., 2010; Dietrich and Geier, 2014) . Several attempts have been made to predict DIC or DILI in humans from in vitro BSEP inhibition data due to limited translatability of hepatic adverse events from preclinical models (Olson et al., 2000) . Recently, Dawson et al. (2012) and Morgan et al. (2013) demonstrated that potent BSEP in vitro inhibition and high systemic drug exposure correlates with the occurrence of DIC. However, the assessments did not allow clearly separating cholestatic/mixed from non-cholestatic drugs, and thus reliable prediction of DIC remains challenging.
Clinical drug toxicity, drug-drug interactions (DDI) and pharmacological drug-target interactions are commonly anticipated by relating the in vitro target potency (IC 50 , K i 
or EC 50
This article has not been copyedited and formatted. The final version may differ from this version. (Muller and Milton, 2012; Zamek-Gliszczynski et al., 2013 ). This assessment is based on the "free drug hypothesis", which assumes complete distribution equilibrium of the unbound drug between blood and tissue at steady-state. This assumption, however, is unlikely to apply for organs such as the liver, where the distribution equilibrium is affected by active cellular transport and metabolic processes .
Therefore, recent publications proposed to estimate the unbound intracellular liver concentration using the liver-to-blood partition coefficient for unbound drug at steady-state (Kp uu ) in vitro (Yabe et al., 2011; Mateus et al., 2013; Pfeifer et al., 2013; Shitara et al., 2013; Nicolai et al., 2015) . Following the concept of the hepatic Extended Clearance Model (ECM), the in vitro (hepatocyte-to-medium) Kp uu can be derived from in vitro measurements of individual hepatic elimination process clearances (sinusoidal influx and efflux, metabolism and biliary secretion), which govern hepatic elimination ( Fig. 1 ) (Shitara et al., 2013; Camenisch et al., 2015; Camenisch, 2016) . Measurements of individual hepatic process clearances additionally allow assignment of compounds into four distinct ECM categories to anticipate class-dependent effects on Kp uu and, as a consequence, on the unbound intracellular concentration (Fig. 2) Camenisch, 2016) .
The aim of the present study was to identify the reference drug concentration (unbound systemic, unbound hepatic inlet or unbound intrahepatic concentration) that provides the best anticipation of DIC risk due to BSEP inhibition. Upon assessing in vitro-in vivo correlation (IVIVC) for Kp uu in rat using literature data, we experimentally determined human hepatic in vitro Kp uu values using the ECM concept for 18 drug compounds with diverse physicochemical and pharmacokinetic properties. Unbound intrahepatic concentrations in human were estimated by applying ECM-based Kp uu to either unbound systemic or hepatic inlet concentrations. The resulting safety margins between in vitro BSEP IC 50 and the various reference concentrations were compared to the clinical incidence of DIC. In addition, the potential impact of genetic and physiological risk factors on the induction of cholestasis is discussed using bosentan as tool compound.
This article has not been copyedited and formatted. The final version may differ from this version. Determination of hepatic in vitro Kp uu . Previous work performed by our group has shown that in vivo hepatic organ clearances (CL h ) were correctly predicted by feeding up-scaled in vitro hepatic process clearances into the ECM (eq. 1) and by applying the "well-stirred" liver model (eq. 2) Umehara and Camenisch, 2012; :
where CL h,int is the intrinsic hepatic clearance, PS inf is the sum of active (PS inf,act ) and passive uptake membrane permeability (PS inf,pas ), PS eff is the sum of active (PS eff,act ) and passive sinusoidal efflux membrane permeability (PS eff,pas ), CL int is the sum of intrinsic metabolic (CL int,met ) and biliary clearances (CL int,sec ), Q h is the hepatic blood flow and fu b is the unbound fraction in blood.
This in vitro-in vivo extrapolation (IVIVE) approach for human and rat hepatic clearance provided a good prediction accuracy for a diverse dataset of 13 compounds with ~80% within two-fold error Umehara and Camenisch, 2012) . According to the concept of the ECM, the intrinsic clearance is driven by the intracellular concentration (Shitara et al., 2013) and eq. 1 can be rearranged as follows:
Hepatic process clearances. Hepatic process clearances for 18 test compounds were experimentally determined as previously described in full detail elsewhere (Camenisch and This article has not been copyedited and formatted. The final version may differ from this version. Umehara and Camenisch, 2012; Kunze et al., 2014; Kunze et al., 2015) . All presented in vitro data for atorvastatin, cerivastatin, cyclosporine A, fluvastatin, ketoconazole, lovastatin acid, pitavastatin, pravastatin, rosuvastatin, simvastatin acid and verapamil were taken from Camenisch and Umehara (2012) and Kunze et al. (2015) .
Briefly, PS inf,act and PS inf,pas were determined in pooled suspended human hepatocytes using the oil-spin method. PS inf,act and PS inf,pas represent single time point measurements within the linear time and concentration range, PS inf,pas was determined in the presence of uptake transporter inhibitors or at high substrate concentrations where active transport processes are known to be saturated. Measured (apparent) uptake clearances were corrected for nonspecific binding to the assay device using radioactivity recoveries and for saturable binding to cell surfaces using data from control incubations at 4°C (Kunze et al., 2014) . For the highly lipophilic compounds ketoconazole and atazanvir (logD 7.4 > 4) PS inf was determined from the slope of initial uptake velocity (3 time points between 0.5 -3 min) taking into account initial cellular binding and non-specific binding to the assay device.
PS eff was assumed to occur only via passive diffusion and to be equal to PS inf,pas (PS eff,act = 0, PS eff,pas = PS inf,pas ).
Apparent metabolic clearance (CL int,met,app ) was determined using human liver microsomes.
Incubations with all test compounds were performed in the presence of nicotinamide adenine 
Values for fu mic and corresponding literature references are provided in Supplemental Table   4 .
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fu hep values were derived from logD 7.4 as follows (Yabe et al., 2011) :
Values for logD 7.4 and corresponding literature references are provided in Supplemental Calculation of unbound drug concentrations in the systemic circulation, at the hepatic inlet and in the hepatocyte. Unbound drug concentrations in blood and plasma are equal (Kwon, 2001 ) and herein referred to as unbound systemic drug concentrations (C sys,u ). C sys,u was calculated from the total maximum available drug plasma concentration (C max ) at steadystate upon oral administration of the maximum recommended dose in healthy human subjects and the fraction unbound in plasma (fu p ):
Unbound drug concentrations at the hepatic inlet (C inlet,u ) were calculated according to eq. 8
as the sum of drug in the systemic circulation reaching the liver via the hepatic artery (i.e.
C sys,u ) and drug that is delivered by the portal vein upon intestinal absorption (Giacomini et al., 2010) :
where k a is the absorption rate constant, F a is the fraction absorbed, F g is the fraction escaping gut metabolism, D is the maximum recommended single oral dose, Q h is the hepatic blood flow (1.45 l/min) and R b is the blood-to-plasma partition coefficient.
This article has not been copyedited and formatted. The final version may differ from this version. Additionally, maximum unbound hepatic inlet concentrations (C inlet,max,u ), representing a "worst-case", were calculated according to eq. 8 assuming complete and fast drug absorption (i.e. F a x F g = 1 and k a = 0.1 min -1 ) (Ito et al., 1998) .
Unbound intracellular drug concentrations in the hepatocyte (hereafter referred as unbound intrahepatic concentration (C hep,u )) were either calculated on basis of C sys,u (eq. 9), C inlet,u (eq.
10) or C inlet,max,u (eq. 11):
All clinical exposure data, pharmacokinetic parameters and calculations thereof are provided in the supplemental material together with the corresponding literature references (Supplemental Tables 2 -4) .
Human BSEP IC 50 values.
In vitro IC 50 data for BSEP inhibition were collected from the literature. In case of multiple reported values the lowest one was used for risk assessments (Table 1) , while Supplementary Table 5 shows the range of reported data. All data have been determined under comparable conditions using membrane vesicles expressing human BSEP with [
DMD #74179
12 cholestasis". The threshold of 2% was selected based on literature information from clinical reports or from the drug label, where rare adverse events were commonly defined as < 2%.
Detailed cholestasis annotations and literature references are summarized in Supplemental Table 5 .
Data analysis. The DIC risk was assessed based on safety margins, calculated as the ratio between BSEP IC 50 and the unbound intrahepatic drug concentration. Following the static Rvalue approach for reversible enzyme or transporter inhibition and using C max,u as basis for unbound intrahepatic concentrations the assessment represents a "worst-case" scenario for DIC (Rowland and Matin, 1973) . Receiver operating characteristic (ROC) curve analysis 
The separation of cholestasis classes by the estimated safety margin thresholds was compared using the area under the ROC curves (ROC AUCs), were 1.0 represents a perfect discrimination between two classes and 0.5 represents the poorest discrimination. 13 (Dingemanse and van Giersbergen, 2004) . The resulting hepatic inlet and intrahepatic concentrations were calculated according to eq. 8 and 10 using a C sys,u value of 0.1327 µM.
The effect of nonsynonymous polymorphisms of hepatic metabolic enzymes and transporters on the in vitro Kp uu of bosentan was calculated according to eq. 13 using measured in vitro process clearances (Table 1) , their fractional in vivo contributions (fn) and reported fold changes in activity compared to the reference genotype (α):
The α values used were determined from the following data: Increased activity was reported for the organic anion transporting polypeptide (OATP) variants OATP1B1*1b and OATP1B3*2 (α OATP1B1 = α OATP1B3 = 2) (Rowland and Matin, 1973; Letschert et al., 2004) . The cytochrome P450 (CYP) variants CYP3A4*20 and CYP2C9*3 are associated with loss-of function (α CYP3A4 = α CYP2C9 = 0) (Lee et al., 2002; Werk and Cascorbi, 2014) , similar to the multidrug resistance protein (MRP) 2 variant MRP2*16 (c.2302C>T) (α MRP2 = 0) (Hulot et al., 2005; Pratt et al., 2015) . According to the literature OATP1B1 and OATP1B3 equally contribute to the total active hepatic uptake of bosentan (fn OATP1B1 = fn OATP1B3 = 0.5) (Treiber et al., 2007) . Hepatic metabolism is mediated by CYP3A4 (fn CYP3A4 = 0.6) and CYP2C9
(fn CYP2C9 = 0.4) (Dingemanse and van Giersbergen, 2004) , and biliary secretion is mediated by MRP2 (fn MRP2 = 1.0) (Fahrmayr et al., 2013) .
To estimate the potential impact of BSEP polymorphisms on the DIC safety margin, reduced BSEP activity was assumed to mimic an increased inhibition potential, where 100% activity corresponds to the BSEP IC 50 value of bosentan (22 µM). According to the literature, BSEP G855R (c.2563G>A) has < 20% transport activity compared to non-polymorphic BSEP (Lang et al., 2007) , which was simulated using a 5-fold reduced BSEP IC 50 value (4.4 µM).
This article has not been copyedited and formatted. The final version may differ from this version. Umehara and Camenisch, 2012; . To further validate the ECM concept, we performed an IVIVC for Kp uu in rat using published in-house data (Fig. 4) . In addition, IVIVC of (Yabe et al., 2011; Shitara et al., 2013) and from sandwich-cultured hepatocytes (Pfeifer et al., 2013) are shown in Fig. 4 Correlation between BSEP inhibition, drug concentrations and drug induced cholestasis. The assignment of the 18 test drug compounds into the three cholestasis frequency classes ("no", "rare", "common") is shown in Table 2 . Risk assessments with regard to DIC were conducted using safety margins calculated as the ratio of BSEP IC 50 and either unbound extracellular drug concentrations (C sys,u or C inlet,u ) or unbound intracellular concentrations upon application of Kp uu (C hep,sys,u or C hep,inlet,u ) (Fig. 5) . The risk assessment with unbound systemic concentrations showed a separation between drugs in cholestasis classes "common" and "no cholestasis" while drugs in the class "rare" markedly overlapped with drugs in the other classes (Fig. 5A) . The separation of drugs in cholestasis class "rare" from "common" or "no cholestasis" was not improved by using the substantially higher unbound drug concentrations at the hepatic inlet (Fig. 5B ). This incomplete separation of the cholestasis classes based on extracellular concentrations is reflected by ROC AUC values of 0.83 -0.94. In contrast, the use of unbound intrahepatic drug concentrations following Kp uu correction markedly enhanced the separation between the three cholestasis classes. The risk assessment based on C hep,sys,u provided a good separation between the three classes with only one drug (rosiglitazone, class "no") being clearly mispredicted (Fig. 5C ). The risk assessment was further improved by using Kp uu -corrected unbound hepatic inlet concentrations. Using this reference concentration an almost complete separation of all drugs into classes "no", "rare" and "common" was achieved (Fig. 5D) , as supported by ROC AUC values of ≥ 0.97. Using C hep,inlet,u as a reference, safety margin thresholds between classes "common"/"rare" and "rare"/"no" of 26 and 529 were obtained, respectively (Fig. 5D ).
These thresholds are clearly lower than those obtained from risk assessments using unbound extracellular concentrations ( Fig. 5A and 5B; "common"/"rare": 100 and 59, "rare"/"no": 3821 and 728 for C sys,u and C inlet,u , respectively). Using C hep,inlet,u the safety margin of simvastatin was reduced to 584-fold compared to 69667-fold based on C hep,sys,u , representing the largest safety margin change within our test set.
Additionally, maximum ("worst-case") unbound hepatic inlet concentrations (C inlet,max,u ) were calculated in order to represent the situation during early drug development where no clinical data are available. Assuming fast and complete intestinal absorption, substantially higher unbound intrahepatic concentrations were obtained than using measured clinical parameters.
While the resulting ratios still allowed to separate "common" from "rare" cholestasis events, the separation between "no" and "rare" was poorer than that obtained in risk assessments based on measured clinical parameters ( Fig. 5D vs 5E ).
Quantification of risk factors for DIC. The theoretical impact of disease state and
polymorphic hepatic enzymes and transporters on bosentan-induced cholestasis was estimated based on clinical systemic exposure and in vitro enzyme and transporter polymorphism data (Fig. 6) . The systemic exposure of bosentan is reported to be ~2-fold higher in PAH patients compared to healthy subjects (Dingemanse and van Giersbergen, 2004) . Based on this, we calculated the corresponding C hep,inlet,u in PAH patients (0.1901 µM), which is 69% higher than in healthy subjects (Fig. 6 , "healthy" vs "PAH patients"). Next, we calculated Kp uu , C hep,inlet,u and corresponding safety margins for bosentan using altered transporter and enzyme activities due to genetic polymorphisms according to eq. 13. Our assessment indicates that the increased transport activity of OATP1B1*1b or OATP1B3*2 variants would increase Kp uu and C hep,inlet,u by 17% (Fig. 6 , "PAH patients" vs "OATP1B1*1b"
This article has not been copyedited and formatted. The final version may differ from this version. vs "CYP3A4*20" or "CYP2C9*3" or "MRP2*16"). Assuming concurrence of all these genetic variants leads to predicted increases of Kp uu and C hep,inlet,u by 70% and a reduction of the safety margin from 116 to 68 (Fig. 6 , "PAH patients" vs "CYP3A4*20, CYP2C9*3, MRP2*16, OATP1B1*1b, OATP1B3*2"). Additionally, we evaluated the potential impact of BSEP polymorphisms on the DIC risk assessment. Presence of the low activity variant BSEP G885R was simulated using a 5-fold reduced BSEP IC 50 value (4.4 µM). This estimation leads to a 23-fold safety margin (Fig. 6 , "PAH patients" vs "BSEP G885R"). The theoretical combination of the BSEP G885R variant with genetic variants that affect the Kp uu of bosentan would even further increase the DIC risk as shown in Fig. 6 ("PAH patients" vs "BSEP G885R, CYP3A4*20, CYP2C9*3, MRP2*16, OATP1B1*1b, OATP1B3*2").
Discussion
In the present work we compare the use of unbound extracellular (systemic and hepatic inlet)
or Kp uu -based intrahepatic concentrations in risk assessments of cholestasis upon BSEP inhibition.
Our work follows up on recent studies, which investigated the impact of systemic drug exposure on the clinical manifestation of DIC or DILI. Using safety margin ratios of BSEP IC 50 to systemic drug concentration, our analyses revealed a generally increased risk of DIC among drugs with lower safety margins (Fig. 5A) . However, no reliable separation of cholestatic and non-cholestatic drugs was obtained from this assessment. The outcome was not improved when hepatic inlet concentrations were used for safety margin calculations (Fig. 5B) , even though this concentration is considered as most relevant with regards to inhibition of hepatic enzymes or transporters (Zamek-Gliszczynski et al., 2013) . These observations based on extracellular concentrations are in line with the previous studies using similar approaches (Dawson et al., 2012; Morgan et al., 2013; Shah et al., 2015) . However, several differences to previous work are important to highlight: 1) Following the "free drug hypothesis" we used only unbound drug concentrations rather than total drug concentrations.
Indeed, we obtained poorer predictions of DIC using total drug concentrations in plasma or blood (data not shown); 2) We evaluated the association of BSEP inhibition with DIC only and not with other types of liver toxicity. Hepatocellular DILI cases, which are included in other studies, are rather caused by direct toxicity or immune-mediated reactions (Chen et al., 2015) and are likely not explained by BSEP inhibition; 3) We classified the investigated drugs according to the DIC incidence instead of a commonly used DILI severity grading (Chen et al., 2011; Pedersen et al., 2013; Aleo et al., 2014) ; 4) The present assessment represents a "worst-case" scenario using the lowest reported in vitro BSEP IC 50 (variability in IC 50 values was within a 3-fold range for the majority of dugs with exception of cyclosporine A, erythromycin, glibenclamide and rosiglitazone) and the maximum reported systemic drug concentration at steady-state after administration of the highest recommended oral dose. At least for certain drugs (e.g. C sys,u of atorvastatin and rosiglitazone), our parameters significantly deviate from previous studies (Dawson et al., 2012; Morgan et al., 2013; Shah et al., 2015) .
However, relating extracellular drug concentrations to inhibition of an intracellular liver target (BSEP) is not expected to provide meaningful risk estimations if intracellular drug concentrations are affected by active transport or metabolic processes (Dawson et al., 2012; Chu et al., 2013; Camenisch et al., 2015; Camenisch, 2016) . Indeed, applying the in vitro
Kp uu values to obtain unbound intrahepatic drug concentrations markedly improved the separation of cholestasis classes. This became particularly evident for the correlation with unbound intrahepatic concentrations based on hepatic inlet concentrations, where almost complete separation between the different cholestasis classes was obtained (Fig. 5D ). The use of hepatic inlet concentrations is most important for drugs with high hepatic first-pass elimination and significantly reduced systemic concentrations, as observed for simvastatin (115-fold difference between C sys,u and C inlet,u ). We therefore conclude that the unbound intrahepatic drug concentration based on hepatic inlet concentrations clearly represents the most reliable reference concentration for prediction of the DIC risk using BSEP inhibition assays.
BSEP in vitro inhibition data are commonly generated in early drug development. However, at this stage clinical drug exposure data are rarely available and DIC risk assessments based on the presented approach are not possible. We therefore performed an alternative risk assessment assuming that the clinical systemic exposure can accurately be predicted and assuming complete and rapid absorption to obtain "worst-case" hepatic inlet concentrations (Fig. 5E ) (Ito et al., 1998; Giacomini et al., 2010) . While the cholestasis classes "common"
and "rare" were reasonably-well separated by this approach, the separation between classes "no cholestasis" and "rare" failed compared to risk approaches using measured clinical input parameters ( Fig. 5D vs Fig. 5E ). For DIC risk assessments during preclinical development, we therefore suggest to apply unbound intrahepatic drug concentrations derived from in vitro Kp uu and predicted systemic exposure (e.g. using PBPK modeling). well with the four ECM classes (Fig. 2, Fig. 3 ). For drugs in ECM classes 1 and 3, where hepatic uptake is the rate-limiting elimination step, Kp uu is likely to be below 1 (C hep,u < C u ).
On the other hand, class 3 drugs can also approach Kp uu above 1 if active hepatic uptake is extensive (C hep,u > C u ). As illustrated in Fig. 7 , unbound extracellular concentrations of ketoconazole and simvastatin acid markedly overestimated the DIC risk. Use of Kp uucorrected unbound intrahepatic concentrations shifted ketoconazole (Kp uu = 0.32) and simvastatin acid (Kp uu = 0.39) into their appropriate risk zones ("rare" and "no" cholestasis, respectively). For class 4 drugs, passive uptake/efflux permeability exceeds intrinsic hepatic clearance. In combination with active hepatic uptake processes, drugs accumulate within the hepatocytes resulting in Kp uu values greater 1 (Fig. 2, Fig. 3 ). For these drugs the DIC risk is underestimated by unbound extracellular concentrations as highlighted for pitavastatin in Fig. 7. After correction with Kp uu pitavastatin was assigned to the correct risk zone ("rare"). Only for class 2 drugs such as imatinib do unbound extracellular concentrations represent an appropriate surrogate for the unbound intrahepatic concentration (Kp uu ≈ 1.0, C hep,u ≈ C u ) (Fig. 7) .
For the in vitro Kp uu assessment we generally assumed absence of active sinusoidal efflux.
Kp uu values of substrates for basolateral MRP3 and MRP4, which have been shown to be upregulated in human and rat under cholestatic conditions (Soroka et al., 2001; Gradhand et al., 2008) , might therefore be over-predicted. However, except for rosuvastatin, the relevance of MRP3 and MRP4 in transport of pharmaceutical drugs is unknown and requires further research. In addition, we assumed that the ECM-based in vitro Kp uu directly translates to in vivo Kp uu . The assumption was based on the good IVIVC for Kp uu in rat (Fig. 4) and on previous hepatic clearance predictions using the ECM, where no systematic under-prediction of in vivo hepatic clearance was observed. Similarly, in vitro Kp uu using sandwich-cultured hepatocytes recently provided a close IVIVC in rat for rosuvastatin, ritonavir and furamidine (Pfeifer et al., 2013) , whereas Kp uu from suspended hepatocytes generally over-predicted Kp uu in vivo, likely due to the absence of intrinsic clearance processes. Partial loss of activity in certain in vitro systems has previously been described (Lundquist et al., 2014) , however, the need of scaling factors for PK modeling is controversially discussed and likely compounddependent requiring clinical data (Jones et al., 2012; Morse et al., 2015; Yoshikado et al., 2016) . Especially in an early drug development stage the direct use of in vitro Kp uu is therefore expected to enable estimations of unbound intrahepatic drug concentrations.
Our risk assessment using unbound hepatic inlet concentrations predicted a DIC risk in more than 2% of subjects for safety margins below ~25 (Fig. 5D ). Since unbound intracellular concentrations are 25-fold below the IC 50 of BSEP, no relevant inhibition of BSEP would be expected. However, the occurrence of DIC in few percent of patients leads us to the hypothesis that these subjects react more sensitively to BSEP inhibition than the rest of the population. This variability might be explained by various physiological (e.g. age, gender, underlying diseases), exogenous (e.g. co-medication, nutrition) and genetic factors (polymorphisms) that potentially modify intrahepatic drug concentrations or BSEP activity, resulting in increased cholestasis risk. Using bosentan as an example we evaluated the theoretical impact of disease state and polymorphic hepatic enzymes and transporters on the DIC risk (Fig. 6) . Physiological factors such as increased age and gender are not associated with altered risk of bosentan-induced cholestasis (Markova et al., 2013) . Similarly, increased systemic bosentan exposure in PAH patients could not be linked to higher incidence of liver injury (Dingemanse and van Giersbergen, 2004) , which is in line with our assessment (Fig.   6 ). The present analysis suggests that genetic variants of transporters and enzymes involved in bosentan elimination only marginally affect the DIC risk assessment, even upon the unlikely concurrence of all polymorphisms (Fig. 6) . Indeed, bosentan-induced liver injury could not be associated with polymorphic variants of OATP1B1, OATP1B3, CYP2C9 or MRP2 (Markova et al., 2013; Markova et al., 2014; Roustit et al., 2014) . In addition, we evaluated the impact of the BSEP variant G885R, which was recently associated with DIC, likely due to substantially reduced activity (< 20%) (Lang et al., 2007) . Based on this data, we estimated a significantly increased risk of bosentan-induced cholestasis in PAH patients carrying the G885R variant as indicated by a 23-fold safety margin and the change in cholestasis class from "rare" to "common" (Fig. 6 ). In summary, the presented risk assessment for bosentan illustrates the utility of ECM-based Kp uu assessments in order to define the relevance of polymorphic enzymes and transporters in the hepatic elimination of a drug. Especially for drugs with high risk of DIC such information could guide the selection of genotyping targets in clinics and ultimately allow providing personalized dosing regimens.
However, further research on frequency, global distribution and in vivo effects of polymorphisms will be required to estimate the incidence of DIC in heterogenic populations.
In conclusion, we demonstrated that the incidence of DIC upon BSEP inhibition correlates with Kp uu -based unbound intrahepatic drug concentrations. To the best of our knowledge, this approach represents the most reliable prediction of DIC available so far, which in addition allows to account for polymorphisms on hepatic enzymes and transporters associated with DIC risk. Our study represents a proof-of-concept for estimating the inhibition and/or passive diffusion (PS eff,pas ).
FIG. 2. Drug classification according to ECM and expected impact on Kp uu and C hep,u .
ECM class 1/2 was assigned if PS eff < CL int , otherwise class 3/4. Class 1/3 was assigned if PS eff = PS inf , otherwise class 2/4. In the present study, PS eff was assumed to occur only via passive diffusion and to be equal to PS inf,pas (PS eff = PS inf,pas ). Adapted from Camenisch et al. (2015) .
FIG. 3. ECM class-dependent impact of experimentally determined hepatic process
clearances on K p,uu and C hep,u . The black lines represent the x-fold change of intrahepatic concentrations (C hep,u ) depending on Kp uu . X-fold increase and decrease in C hep,u corresponds to Kp uu and 1/Kp uu , respectively. White, grey and dark grey bars represent the underlying process clearances (active uptake, sum of passive uptake and efflux, and intrinsic clearance, respectively), which affect Kp uu , as described in Fig. 2 . Hepatic process clearances refer to the left y-axis whereas changes in C hep,u refer to the right y-axis. classes "common"/ "rare" (26-fold) and "rare"/ "no" (529-fold), respectively.
FIG. 4. In vitro-in vivo
This article has not been copyedited and formatted. The final version may differ from this version. ECM classes were derived as described in Fig. 2 . Unbound extracellular (systemic and hepatic inlet) and intracellular concentrations were Bosentan was assigned to the classes "common" and "rare" depending on the administered dose (1000 and 125 mg twice daily (bid), respectively). Literature references and detailed annotations are summarized in Supplemental Table 5 .
